Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Algert Global LLC Buys 39,586 Shares of Charles River Laboratories International, Inc. $CRL
03:27am, Sunday, 15'th Mar 2026
Algert Global LLC increased its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 54.0% in the third quarter, according to the company in its most recent filing with the Securitie
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:10pm, Tuesday, 10'th Mar 2026
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Cresset Asset Management LLC Has $1.36 Million Stock Position in Charles River Laboratories International, Inc. $CRL
04:37am, Tuesday, 10'th Mar 2026
Cresset Asset Management LLC boosted its position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 57.4% in the undefined quarter, according to its most recent filing with th
Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:32pm, Tuesday, 03'rd Mar 2026
Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Charles River Laboratories to Present at TD Cowen and Barclays Conferences
08:00am, Monday, 02'nd Mar 2026
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at TD Cowen and Barclays Conferences.
Charles River raises annual profit view as it sells underperforming assets
08:00am, Wednesday, 25'th Feb 2026
Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Pa
Charles River Laboratories Provides Update on Planned Divestitures
07:00am, Wednesday, 25'th Feb 2026
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 24'th Feb 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investing in Charles River (CRL)? Don't Miss Assessing Its International Revenue Trends
10:16am, Monday, 23'rd Feb 2026
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Charles River Laboratories International Inc (CRL) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic Acquisitions
04:06pm, Wednesday, 18'th Feb 2026
Fourth Quarter Revenue: $994.2 million, a 2.6% decline on an organic basis.Full Year Revenue: $4.02 billion, with an organic revenue decrease of 1.6%.Operating
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
01:54pm, Wednesday, 18'th Feb 2026
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories Q4 Review: Approaching A Bottom
11:20am, Wednesday, 18'th Feb 2026
Charles River Laboratories Q4 Review: Approaching A Bottom
Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings
10:31am, Wednesday, 18'th Feb 2026
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall
CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
09:55am, Wednesday, 18'th Feb 2026
Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
09:11am, Wednesday, 18'th Feb 2026
Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.
